← Back to Clinical Trials
RecruitingPhase 4NCT07424014

The Role of Heliox in Respiratory Control

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionWork of Breathing
SponsorIndiana University
Study TypeINTERVENTIONAL
PhasePhase 4
Enrollment15
SexALL
Min Age18 Years
Max Age40 Years
Start Date2026-02-03
Completion2027-05-31
Interventions
Heliox inspirate

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Warfighters are frequently exposed to environments and life-support systems that increase breathing resistance and the work of breathing (WOB), such as aircraft on-board oxygen generation systems and underwater breathing apparatuses. Elevated WOB increases the perception of breathing difficulty (dyspnea) and has been associated with impaired cognitive performance, including slower reaction time and reduced accuracy during attention-demanding tasks. These effects are particularly concerning in operational settings that require rapid decision-making and precise motor responses. Despite growing recognition of this issue, critical gaps remain regarding strategies to mitigate the perceptual and cognitive consequences of elevated inspiratory resistance, especially under realistic operational stressors. The objective of this study is to determine whether reducing mechanical WOB alters breathing perception and cognitive performance during inspiratory resistance. Participants will breathe either normal-density air or a low-density helium-oxygen gas mixture (heliox) to determine whether reducing mechanical WOB lowers perceived breathing effort and improves cognitive function.

Eligibility Criteria

Inclusion Criteria: * Between the ages of 18-40 years old. * English speaking and reading. * Self-reported weekly activity of at least 120 minutes/week of high intensity exercise for the previous 2 years. * Normal pulmonary function assessed by a resting forced expiratory volume in 1 second over forced vital capacity (FEV1/FVC) \> 75% of predicted. * Normal cognitive function assessed using the Montreal cognitive function test \[18\]. * Body mass index (BMI) ≤ 35 kg/m2. * Females with a regular menstrual cycle that ranges from 21-35 days (eumenorrhea) Exclusion Criteria: * History of smoking or recreational smoking, cardiovascular disease, renal disease, pulmonary disease (including asthma or exercise-induced asthma), neurological disease, and metabolic disease. * Are pregnant or could possibly be pregnant by self-report. * Are color blind. * Known allergy or hypersensitivity latex. * Take selective serotonin reuptake inhibitors, stimulant medication, antibiotics, and chronically consu

Related Trials